Physician profile
Katherine E Cox-Flaherty
NPI 1427476290
$880.98
in general payments reported to CMS, 2019-2025
11 companies · $503 in 2025
The $503 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $378 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $198.64 | 2024-2025 | Fasenra, Airsupra |
| Pulmonx Corporation | $160.75 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Electromed, INC. | $117.69 | 2024 | Smartvest |
| Inari Medical, INC. | $107.62 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $86.79 | 2024-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $67.16 | 2025 | Tezspire |
| Genzyme Corporation | $61.76 | 2024-2025 | |
| Verona Pharma, INC. | $49.20 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $15.87 | 2024 | |
| Insmed, INC. | $15.50 | 2025 | Arikayce |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Cox-Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.